114 related articles for article (PubMed ID: 8877596)
1. Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers.
Bellissant E; Nguyen PC; Giudicelli JF
J Cardiovasc Pharmacol; 1996 Sep; 28(3):470-8. PubMed ID: 8877596
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers.
Bellissant E; Giudicelli JF
Br J Clin Pharmacol; 1998 Oct; 46(4):383-93. PubMed ID: 9803988
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients.
Bellissant E; Giudicelli JF
Br J Clin Pharmacol; 2001 Jul; 52(1):25-33. PubMed ID: 11453887
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers.
Bellissant E; Giudicelli JF
Br J Clin Pharmacol; 1999 Dec; 48(6):801-10. PubMed ID: 10594483
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure.
Bellissant E; Chau NP; Thuillez C; Gerbeau C; Richard C; Giudicelli JF
J Cardiovasc Pharmacol; 1997 Aug; 30(2):253-60. PubMed ID: 9269955
[TBL] [Abstract][Full Text] [Related]
6. Sex-related pharmacokinetic and pharmacodynamic variations of lisinopril.
Sáenz-Campos D; Bayés MC; Masana E; Martín S; Barbanoj M; Jané F
Methods Find Exp Clin Pharmacol; 1996 Oct; 18(8):533-8. PubMed ID: 9044242
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive assessment of regional arteriolar and arterial dilating properties of lisinopril in healthy volunteers.
Bellissant E; Thuillez C; Richer C; Pussard E; Giudicelli JF
J Cardiovasc Pharmacol; 1994 Sep; 24(3):500-8. PubMed ID: 7528307
[TBL] [Abstract][Full Text] [Related]
8. Kinetic-dynamic relations and individual responses to enalapril.
Donnelly R; Meredith PA; Elliott HL; Reid JL
Hypertension; 1990 Mar; 15(3):301-9. PubMed ID: 2154407
[TBL] [Abstract][Full Text] [Related]
9. Effects on plasma angiotensin-converting enzyme activity and circulating renin of lisinopril and enalapril alone and in combination with propranolol in healthy volunteers.
Hansen EF; Bendtsen F; Henriksen JH
Pharmacol Toxicol; 1999 Mar; 84(3):110-4. PubMed ID: 10193670
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment.
Neubeck M; Fliser D; Pritsch M; Weisser K; Fliser M; Nussberger J; Ritz E; Mutschler E
Eur J Clin Pharmacol; 1994; 46(6):537-43. PubMed ID: 7995322
[TBL] [Abstract][Full Text] [Related]
11. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles.
Hamlin RL; Nakayama T
J Vet Intern Med; 1998; 12(2):93-5. PubMed ID: 9560765
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor.
Denti P; Sharp SK; Kröger WL; Schwager SL; Mahajan A; Njoroge M; Gibhard L; Smit I; Chibale K; Wiesner L; Sturrock ED; Davies NH
Eur J Pharm Sci; 2014 Jun; 56():113-9. PubMed ID: 24561703
[TBL] [Abstract][Full Text] [Related]
13. [Modeling of the relation between plasma concentration of the active metabolite of perindopril and inhibition of the activity of plasma converting enzyme in healthy volunteers].
Bellissant E; Chau NP; Thuillez C; Giudicelli JF
Arch Mal Coeur Vaiss; 1990 Jul; 83(8):1285-9. PubMed ID: 2175584
[TBL] [Abstract][Full Text] [Related]
14. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
Westendorp B; Schoemaker RG; van Gilst WH; van Veldhuisen DJ; Buikema H
Eur J Pharmacol; 2005 Dec; 527(1-3):141-9. PubMed ID: 16310764
[TBL] [Abstract][Full Text] [Related]
15. ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.
Sacco G; Mario B; Lopez G; Evangelista S; Manzini S; Maggi CA
Vascul Pharmacol; 2009; 50(5-6):166-70. PubMed ID: 19344651
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure.
Dickstein K
J Cardiovasc Pharmacol; 1987; 9 Suppl 3():S73-81. PubMed ID: 2442558
[TBL] [Abstract][Full Text] [Related]
17. Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans.
Cargill RI; Lipworth BJ
Chest; 1996 Feb; 109(2):424-9. PubMed ID: 8620717
[TBL] [Abstract][Full Text] [Related]
18. Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure.
Dickstein K; Aarsland T; Woie L; Abrahamsen AM; Fyhrquist F; Cummings S; Gomex HJ; Hagen E; Kristianson K
Am Heart J; 1986 Jul; 112(1):121-9. PubMed ID: 3014850
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test.
Shin MC; Kim JK; Kim CK
Arzneimittelforschung; 2008; 58(1):11-7. PubMed ID: 18368945
[TBL] [Abstract][Full Text] [Related]
20. Lisinopril and nifedipine: no acute interaction in normotensives.
Lees KR; Reid JL
Br J Clin Pharmacol; 1988 Mar; 25(3):307-13. PubMed ID: 2833920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
